Medtronic SPYRAL HTN-OFF MED trial meets primary & secondary endpoints

Date: 2020-03-30   Author: Saipriya Iyer  Category: #news

Medtronic SPYRAL HTN-OFF MED trial meets primary & secondary endpoints

Medtronic plc, a medical tech, services, and solutions company, has recently announced that the SPYRAL HTN-OFF MED Pivotal Trial, has met its primary and secondary endpoints. The Pivotal Trial, which accompanies the SPYRAL HTN-ON MED Trial & SPYRAL DYSTAL Study, is a part of the SPYRAL HTN Global Clinical Trial Program and involves patients with uncontrolled high BP (blood pressure) who are not consuming anti-hypertensive drugs. These medications were also discontinued for at least 3 weeks prior to the randomization. The study, with no major procedural or device safety events through 3 months, shows the probability of >99.9% superiority for both primary and secondary effectiveness endpoints, versus patients  receiving a sham control procedure.

The sham-controlled trial has evaluated 331 patients, out of which, 166 were randomized to RDN (renal denervation). This has resulted in a significant reduction of 9.2 mm Hg in OSBP (office systolic blood pressure) & 4.7 mm Hg in 24-hour ambulatory systolic BP (ABPM) among the patients who received treatment with the Symplicity Spyral RDN system, at 3 months. The consistent BP reduction throughout day and night offers an advantage among patients as cardiovascular risk tend to be high during nighttime.

FDA also has recently granted a Breakthrough Device Designation to Medtronic for the Symplicity Spyral RDN system, which is limited to investigational use in the U.S., Japan & Canada and approved for commercial use in 60 nations worldwide.

University Hospital Homburg’s chief of cardiology, Prof. Michael Böhm, M.D., Ph.D. has stated that the results from the study further complement the more comprehensive SPYRAL Program that reinforces RDN as a treatment option for uncontrolled hypertension patients.

Dave Moeller, GM and VP of the Coronary & Renal Denervation business, a part of Medtronic’s Cardiac & Vascular Group, has stated that the recent, advanced SPYRAL HTN clinical program will ideally complement traditional uncontrolled hypertension treatments and help fulfil the unmet needs of patients that struggle to adhere to long-term drug therapy.

Source credit:

About Author

Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Antenatal Screening Market Share, By Product Analysis, Application, End-Use, Regional Outlook, Competitive Strategies & Forecast up to 2028

Author: Ashwin Naphade

Global Antenatal Screening Market, 2022-2028 Research Report provides crucial statistics on the market status of the Global Antenatal Screening manufacturers and is a respected source of guidance and direction for companies and individuals interes...

Pediatric Vitrectomy Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2028

Author: Ashwin Naphade

Global Pediatric Vitrectomy market report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The Pediatric Vitrectomy market repor...

Legionnaire Disease Testing Market Comprehensive Analysis, Share, Growth Forecast from 2022 to 2028c

Author: Ashwin Naphade

This report studies the Global Legionnaire Disease Testing market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, ...